Fanning S, Haque A, Imberdis T, et al. Lipidomic Analysis of α-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment. Mol Cell. 2019;73(5):1001-1014.e8. doi:10.1016/j.molcel.2018.11.028.
Cheng Z, Mugler CF, Keskin A, et al. Small and Large Ribosomal Subunit Deficiencies Lead to Distinct Gene Expression Signatures that Reflect Cellular Growth Rate. Mol Cell. 2019;73(1):36-47.e10. doi:10.1016/j.molcel.2018.10.032.
Weinstein ZB, Kuru N, Kiriakov S, et al. Modeling the impact of drug interactions on therapeutic selectivity. Nat Commun. 2018;9(1):3452. doi:10.1038/s41467-018-05954-3.
Kuruvilla FG, Shamji AF, Schreiber SL. Carbon- and nitrogen-quality signaling to translation are mediated by distinct GATA-type transcription factors. Proc Natl Acad Sci U S A. 2001;98(13):7283-8. doi:10.1073/pnas.121186898.
Chen J, Zheng XF, Brown EJ, Schreiber SL. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci U S A. 1995;92(11):4947-51.
Shamji AF, Kuruvilla FG, Schreiber SL. Partitioning the transcriptional program induced by rapamycin among the effectors of the Tor proteins. Curr Biol. 2000;10(24):1574-81.
Floto A, Sarkar S, Perlstein EO, Kampmann B, Schreiber SL, Rubinsztein DC. Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington’s disease models and enhance killing of mycobacteria by macrophages. Autophagy. 2007;3(6):620-2.